¹ Microbiology, Al-Anbar University/ College of Medicine, Ramadi, Al-Anbar, 1111, Iraq
² Pathology, Al-Anbar University/ College of Medicine, Ramadi, Al-Anbar, 1111, Iraq

Ahmed salman
Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Visualization, Writing – Original Draft Preparation

Mothana Khalil
Roles: Supervision

Arkan Al-Esawi
Roles: Supervision

This case-control study was designed to investigate the relationship between EBNA1 and miR-155 expression in papillary thyroid carcinoma among Iraqi patients. The study employed a comparative approach to evaluate expression patterns between PTC cases and benign thyroid nodule controls, with comprehensive clinicopathological correlation.

The study was conducted at two major tertiary care centers in Baghdad, Iraq: Al-Amal National Hospital for Cancer Management and Al-Yarmook Teaching Hospital. The research period spanned from March 2024 to July 2024, encompassing patient recruitment, sample collection, laboratory analysis, and statistical evaluation. These institutions were selected based on their specialized thyroid cancer management services and high patient volume, ensuring adequate sample representation.

The study protocol received approval from the Ethics Committee of the College of Medicine, University of Anbar (Reference No. MCA/2024/TC-15). All procedures were conducted in accordance with the Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants prior to enrollment, with detailed information provided regarding study objectives, procedures, potential risks, and benefits. Participants were assured of data confidentiality and their right to withdraw from the study at any time without affecting their medical care.

Reagents and materials

TRIzol Reagent (Cat# 15596026, 1 mL per sample, Invitrogen, USA); High-Capacity cDNA Reverse Transcription Kit (Cat# 4368814, Applied Biosystems, USA); SYBR Green PCR Master Mix (Cat# 4309155, 25 μL per reaction, Applied Biosystems, USA); miScript II RT Kit (Cat# 218161, Qiagen, Germany); miScript SYBR Green PCR Kit (Cat# 218073, Qiagen, Germany); Nuclease-free water (Cat# AM9937, Ambion, USA); RNase inhibitor (Cat# N8080119, 40 U/μL, Applied Biosystems, USA). All reagents were stored at -20°C or -80°C according to manufacturer’s instructions.

The study population comprised 200 participants divided into two groups: 100 patients with histologically confirmed papillary thyroid carcinoma (cases) and 100 patients with benign nodular goiter (controls). Sample size was calculated using the formula for case-control studies with an expected odds ratio of 3.0, 80% power, and 5% significance level. This calculation indicated a minimum requirement of 94 participants per group, which was increased to 100 to account for potential dropouts and incomplete data.

Inclusion criteria for cases included: (1) age between 18 and 70 years; (2) histopathologically confirmed diagnosis of papillary thyroid carcinoma; (3) no previous history of thyroid surgery or radioiodine therapy; (4) availability of complete clinical and pathological data.

Inclusion criteria for controls included: (1) age between 18 and 70 years; (2) histopathologically confirmed benign nodular goiter; (3) no evidence of malignancy on cytological or histological examination; (4) no previous history of thyroid surgery.

Exclusion criteria for both groups included: (1) presence of other malignancies; (2) autoimmune thyroid diseases; (3) pregnancy or lactation; (4) immunosuppressive conditions or medications; (5) incomplete medical records; (6) refusal to provide informed consent.

Blood samples (5 mL) were collected from all participants using standard venipuncture techniques into EDTA-containing tubes. Samples were collected from PTC patients during pre-operative evaluation or immediately before surgical resection. Control samples were obtained from nodular goiter patients during routine clinical visits. All samples were processed within 2 hours of collection. Serum was separated by centrifugation at 3000 rpm for 10 minutes at 4°C, aliquoted into sterile microcentrifuge tubes, and stored at -80°C until analysis.

Total RNA extraction was performed using TRIzol reagent (Invitrogen, USA) according to the manufacturer’s protocol. Briefly, 200 μL of serum was mixed with 1 mL of TRIzol reagent and incubated for 5 minutes at room temperature. Following chloroform extraction and isopropanol precipitation, RNA pellets were washed with 75% ethanol, air-dried, and resuspended in 30 μL of RNase-free water. RNA concentration and purity were assessed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA), with acceptable A260/A280 ratios between 1.8 and 2.0.

Complementary DNA (cDNA) synthesis was performed using the miScript II RT Kit (Qiagen, Germany) for miR-155 and the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA) for EBNA1 mRNA. Quantitative real-time PCR was conducted using SYBR Green Master Mix (Thermo Fisher Scientific, USA) on a StepOnePlus Real-Time PCR System (Applied Biosystems, USA).

The primers used were: miR-155 stem-loop primer (5'-GCGAGGCGGTGGCAGTGGAAGCGTGATTTATTCACCGCCCTCGCACCCCTAT-3'), forward primer (5'-CTCAGACTCGGTTAATGCTAATGCTAATCGTGATAGGG-3'), and reverse primer (5'-GCTGTGGCAGTGGAAGCGTGATTTATT-3'). For normalization, U6 snRNA was used for miR-155 and GAPDH for EBNA1 mRNA. PCR cycling conditions consisted of initial denaturation at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Relative expression levels were calculated using the 2^-ΔΔCt method.

Because EBNA1 is a viral latency-associated transcript and cell-free serum mRNA is inherently labile, we took several steps to support the validity of this readout. Samples were processed within 2 hours of collection, serum was separated by standardized centrifugation, and aliquots were stored immediately at -80°C to limit degradation; RNA integrity was checked via A260/A280 ratios (accepted range 1.8-2.0) prior to analysis. [Author to complete: describe how PCR product specificity was confirmed for the EBNA1 mRNA assay, e.g., melt-curve analysis showing a single peak, no-template and no-reverse-transcriptase controls, and/or gel electrophoresis/sequencing of the amplicon.] We note that circulating cell-free EBNA1 mRNA has not been widely validated as an analyte compared with tissue-based or cellular EBV DNA measures, and we present this as an exploratory readout requiring further methodological validation (e.g., digital PCR, replicate extractions) in future work.

Comprehensive clinical and pathological data were collected from medical records, including age, gender, tumor size, TNM stage, lymph node involvement, and presence of distant metastasis. Histopathological examination was performed by experienced pathologists to confirm diagnoses and assess tumor characteristics. EBNA1 expression was assessed by two independent methods in this study: (1) tissue immunohistochemistry (IHC), reported as a categorical positive/negative status, and (2) circulating serum EBNA1 mRNA, reported as a continuous quantitative value (see Quantitative real-time PCR analysis above). These two measures are not assumed to be interchangeable, and each result reported in this manuscript is labeled according to which measure it reflects.

Statistical analyses were performed using SPSS version 26.0 (IBM Corp., USA), R software version 4.2.0, and GraphPad Prism version 9.0. Continuous variables were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR) based on distribution normality assessed by the Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages.

Comparisons between groups were performed using Student’s t-test for normally distributed continuous variables and Mann-Whitney U test for non-normally distributed variables. Chi-square test or Fisher’s exact test was used for categorical variables. Correlation analysis was conducted using Pearson’s correlation coefficient. Receiver operating characteristic (ROC) curves were constructed to evaluate diagnostic performance, with calculation of area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Multivariate logistic regression analysis was performed to identify independent predictors of PTC. Statistical significance was set at p < 0.05 for all analyses.

The study cohort comprised 200 participants, equally distributed between PTC cases (n = 100) and nodular goiter controls (n = 100). The demographic characteristics showed no significant differences between groups. The mean age of PTC patients was 45.3 ± 12.1 years compared to 44.8 ± 11.7 years in controls (p = 0.762). Gender distribution revealed a female predominance in both groups, with 72% females in the PTC group and 68% females in the control group (p = 0.537).

Clinical evaluation of PTC cases revealed significant pathological features. Lymph node metastasis was present in 58% of cases, while 42% presented with advanced-stage disease (TNM stage III/IV). The mean tumor size was 2.8 ± 1.4 cm, with 35% of tumors exceeding 4 cm in diameter. Multifocal disease was observed in 28% of cases, and extrathyroidal extension was documented in 23% of patients.

Immunohistochemical analysis revealed striking differences in EBV marker expression between PTC cases and controls ( Table 1). EBNA1 positivity was detected in 82% of PTC cases compared to 41% of controls, representing a statistically significant difference (p < 0.001).

Quantitative real-time PCR analysis revealed significant differences in both miR-155 and EBNA1 expression levels between PTC cases and controls ( Table 2). MiR-155 expression was markedly elevated in PTC cases with a mean fold change of 5.38 ± 2.50 compared to 1.51 ± 1.25 in controls (p < 0.0001), representing a 3.6-fold increase. Similarly, EBNA1 mRNA expression showed significant upregulation in PTC cases (24.3 ± 11.96) compared to controls (15.9 ± 19.20, p < 0.0001).

Further analysis examined miR-155 expression levels based on EBNA1 status across the entire cohort ( Table 3). Among EBNA1-positive participants (n = 123), the mean miR-155 expression was 4.1 ± 2.7, while EBNA1-negative participants (n = 77) showed lower miR-155 expression levels of 2.3 ± 2.4 (p < 0.001). However, EBNA1-positive status was substantially more common among PTC cases (82 of 123 EBNA1-positive participants) than controls (41 of 123), and EBNA1-negative status was correspondingly more common among controls (59 of 77) than cases (18 of 77). Because miR-155 is already markedly higher in cases than controls (Table 2), this unstratified comparison is confounded by case/control group membership and cannot on its own be interpreted as evidence of an EBNA1-specific effect on miR-155. miR-155 expression by EBNA1 status calculated separately within cases and within controls, with corresponding means ± SD and p-values, replacing or supplementing (Table 3).

Correlation analysis was performed to examine the relationship between miR-155 and EBNA1 mRNA expression levels across all participants ( Figure 1). Despite the observed differences in expression patterns between cases and controls, Pearson correlation analysis revealed a weak negative correlation between miR-155 and EBNA1 mRNA expression (r = -0.031, p = 0.758). This finding indicates that miR-155 and EBNA1 mRNA levels are not linearly related, and that while both markers are independently elevated in PTC, this study provides no evidence that one drives the other.

The analysis reveals a very weak negative correlation (r = -0.031) between miR-155 and EBNA1 expression levels. With p = 0.758, this correlation is not statistically significant, suggesting no linear relationship between these two biomarkers despite both being upregulated in PTC.

Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic utility of miR-155 for distinguishing PTC from benign nodular goiter ( Table 4). MiR-155 demonstrated excellent diagnostic performance with an area under the curve (AUC) of 0.927 (95% CI: 0.890-0.958). At the optimal cutoff value of 3.065, miR-155 achieved a sensitivity of 83%, specificity of 87%, positive predictive value of 86.2%, and negative predictive value of 82.1%, resulting in an overall diagnostic accuracy of 84% ( Figure 2).

Analysis of miR-155 expression levels in relation to clinicopathological features revealed significant associations ( Table 5). Higher miR-155 expression was significantly associated with lymph node metastasis (6.42 ± 2.31 vs. 3.94 ± 2.15, p < 0.001), advanced TNM stage (6.87 ± 2.45 vs. 4.31 ± 2.12, p < 0.001), and larger tumor size (>4 cm: 7.12 ± 2.38 vs. ≤4 cm: 4.56 ± 2.24, p < 0.001). These findings suggest that miR-155 expression correlates with aggressive tumor behavior and may serve as a prognostic indicator.

Multivariate logistic regression analysis was performed to identify independent predictors of PTC ( Table 6). After adjusting for age, gender, and other variables, both miR-155 expression (OR = 4.82, 95% CI: 2.34-9.93, p < 0.001) and EBNA1 positivity (OR = 3.15, 95% CI: 1.68-5.91, p < 0.001) remained significant independent predictors of PTC diagnosis.

The significantly higher prevalence of EBV markers in PTC cases compared to controls represents a key finding of this study. The detection of EBNA1 in 82% of PTC cases versus 41% of controls (p < 0.001) aligns with recent investigations demonstrating EBV involvement in thyroid malignancies.¹¹ These findings are consistent with studies by Zhang et al. and Wang et al.,¹² who reported similar patterns of EBV marker expression in thyroid cancer cohorts from different geographical regions.

However, the lower specificity of EBNA1 (59% negative in controls) indicates that while it may contribute to carcinogenesis, its presence alone is insufficient for malignant transformation.

Our observation of significantly elevated miR-155 expression in PTC cases (5.38 ± 2.50) compared to controls (1.51 ± 1.25) corroborates recent meta-analyses identifying miR-155 as a consistently upregulated miRNA in thyroid cancer.¹³ The 3.6-fold increase observed in our cohort is comparable to findings from Chen et al.,¹⁴ who reported similar fold changes in Asian populations. This conservation of expression patterns across different ethnic groups suggests that miR-155 upregulation represents a fundamental feature of PTC biology rather than a population-specific phenomenon.

The parallel upregulation of EBNA1 mRNA in PTC cases provides additional evidence for EBV involvement in thyroid carcinogenesis. The observed expression levels (24.3 ± 11.96 in cases vs. 15.9 ± 19.20 in controls) suggest active viral gene transcription in tumor tissue. Recent mechanistic studies have demonstrated that EBNA1 can directly bind to host chromatin and modulate gene expression, including microRNA genes.¹⁵ This epigenetic modulation may represent one mechanism through which EBV contributes to thyroid cancer development.

The observation that EBNA1-positive samples exhibited higher miR-155 expression (4.1 ± 2.7) compared to EBNA1-negative samples (2.3 ± 2.4) is consistent with, but does not on its own establish, a regulatory relationship between these molecules, because EBNA1-positive status was disproportionately represented among cases; this comparison is addressed further, and stratified by case/control status, in the Results. Studies in other EBV-associated malignancies have reported that EBNA1 can induce miR-155 expression through activation of transcription factors such as NF-κB and STAT3.¹⁵ Research by Liu et al.¹⁵ demonstrated that EBNA1 can enhance miR-155 promoter activity through both direct and indirect mechanisms in those model systems; we cite this as prior evidence from other cancer contexts, not as a mechanism demonstrated in the present dataset.¹⁵

The weak negative correlation (r = -0.031, p = 0.758) between miR-155 and EBNA1 mRNA expression levels indicates that, at the level of continuous expression, these two markers do not move together in our cohort. This contrasts with studies in lymphomas and nasopharyngeal carcinoma, where positive correlations have been reported.¹⁶ We consider several non-mutually-exclusive explanations for why both markers are elevated in PTC without correlating: (1) the relationship between EBNA1 and miR-155 may be non-linear, with threshold effects or saturation kinetics that a linear correlation coefficient would not detect; (2) temporal dynamics may play a role, with any EBNA1 effect on miR-155 occurring earlier in disease development and not persisting proportionally in established tumors; and (3) miR-155 expression in PTC may be driven predominantly by other regulatory mechanisms — other viral proteins, host transcription factors, or epigenetic modifications — largely independent of EBNA1 levels. We emphasize that these are hypotheses for future mechanistic and functional studies (e.g., chromatin immunoprecipitation, reporter assays, EBNA1 knockdown/overexpression models), not conclusions supported by the present cross-sectional dataset.¹⁶

The excellent diagnostic performance of miR-155 (AUC = 0.927, sensitivity = 83%, specificity = 87%) positions it as a promising biomarker for PTC detection ( Figure 2). These results surpass many currently available biomarkers and approach the performance of fine-needle aspiration cytology, the current gold standard for thyroid nodule evaluation.¹⁷ The high positive predictive value (86.2%) suggests that elevated miR-155 levels strongly indicate malignancy, while the negative predictive value (82.1%) provides reasonable confidence in ruling out PTC.

Comparison with recent biomarker studies reveals that miR-155 performs favorably against other proposed markers. A meta-analysis by Liu Y et al.¹⁸ examining multiple miRNAs in thyroid cancer reported average AUCs ranging from 0.75 to 0.88, placing our miR-155 results in the upper performance tier. The integration of miR-155 testing into clinical practice could potentially reduce unnecessary thyroid surgeries by improving preoperative risk stratification of thyroid nodules.

The significant cross-sectional associations between miR-155 expression and adverse clinicopathological features at diagnosis are notable. The associations with lymph node metastasis (p < 0.001), advanced TNM stage (p < 0.001), and larger tumor size (p < 0.001) suggest that miR-155 levels track with markers of tumor aggressiveness at the time of sampling. However, as this study did not include recurrence or survival follow-up, these findings represent cross-sectional clinicopathological correlations rather than demonstrated prognostic value, and we have removed prognostic framing from the title, abstract, and keywords accordingly. These associations are broadly consistent with functional studies demonstrating that miR-155 promotes cancer cell proliferation, migration, and invasion through targeting of tumor suppressor genes including SOCS1, PTEN, and VHL.¹⁹

Whether miR-155 has prognostic value in PTC — for example, for recurrence or treatment response — cannot be assessed from the present cross-sectional dataset, since no follow-up data were collected. Longitudinal studies in other cohorts have suggested that persistently elevated miR-155 levels following treatment correlate with increased recurrence risk.²⁰ This external evidence is a reasonable basis for a future prospective study design, but it is not a finding of the present study, and we have avoided extending it into a conclusion about our own cohort.²⁰

Whether and how EBNA1 might influence miR-155 expression in PTC remains an open question that our data do not resolve. In other EBV-associated cancers, EBNA1 has been reported to bind the miR-155 promoter region in chromatin immunoprecipitation studies,²¹ to activate transcription factors known to regulate miR-155, including NF-κB, AP-1, and STAT3,²² and to influence the epigenetic landscape through interactions with histone modifiers and DNA methyltransferases.²³ We present these as plausible mechanisms drawn from other cancer contexts that could motivate future functional studies in PTC, not as mechanisms demonstrated by the present case-control data.^21–23

The downstream effects of miR-155 upregulation in PTC are multifaceted. Validated targets of miR-155 in thyroid cancer include SOCS1, leading to enhanced JAK/STAT signaling; PTEN, resulting in PI3K/Akt pathway activation; and TGFβ pathway components, promoting epithelial-mesenchymal transition.²⁴ These molecular alterations collectively contribute to the hallmarks of cancer, including sustained proliferation, resistance to apoptosis, and enhanced invasive capacity.

The translation of our findings into clinical practice requires consideration of several factors. First, the development of standardized assays for miR-155 detection in serum or fine-needle aspiration samples is essential. Current variability in RNA extraction methods, normalization strategies, and detection platforms represents a significant barrier to clinical implementation.²⁵ Second, prospective validation studies in larger, multi-center cohorts are needed to confirm diagnostic performance and establish optimal cutoff values for different clinical scenarios.

The therapeutic implications of the EBNA1-miR-155 axis are equally compelling. AntagomiRs targeting miR-155 have shown promise in preclinical models of various cancers and may represent a viable therapeutic strategy for PTC.²⁶ Additionally, targeting EBNA1 through small molecule inhibitors or immunotherapeutic approaches could potentially disrupt multiple oncogenic pathways simultaneously. Recent advances in EBNA1-specific T cell therapies for EBV-associated malignancies provide a template for similar approaches in EBV-positive PTC.

Several limitations of this study warrant consideration. First, the case-control design precludes establishing causality between EBV infection and PTC development. Prospective cohort studies tracking EBV status and thyroid cancer incidence would provide stronger evidence for a causal relationship. Second, the two-center nature of the study may limit generalizability, although the consistency with international findings suggests broader applicability. Third, the lack of functional validation experiments prevents definitive conclusions about any mechanistic relationship between EBNA1 and miR-155. Fourth, the absence of long-term follow-up data limits our ability to assess the prognostic value of these markers for recurrence and survival outcomes. Fifth, because EBNA1 positive and negative groups were not evenly distributed between cases and controls, the unstratified comparison of miR-155 by EBNA1 status (Table 3) is confounded by group membership; stratified analyses are needed to determine whether an EBNA1-associated effect on miR-155 persists within cases and within controls separately. Sixth, serum EBNA1 mRNA as a circulating analyte has not been extensively validated in the literature, and specificity/degradation controls for this assay should be interpreted as exploratory pending further methodological confirmation.

The findings of this study have particular relevance for healthcare in Iraq, where thyroid cancer incidence has been increasing and access to advanced diagnostic technologies may be limited. The development of miR-155-based diagnostic assays could provide a cost-effective screening tool for thyroid nodule evaluation, potentially reducing the burden on surgical services. Additionally, understanding the role of EBV in thyroid cancer may inform public health strategies, particularly given the high prevalence of EBV infection in the region.

The authors express their gratitude to the medical staff at Al-Amal National Hospital for Cancer Management and Al-Yarmook Teaching Hospital for their assistance in patient recruitment and sample collection. We also thank the laboratory technicians for their technical support in sample processing and analysis.

• 1.  Cabanillas ME, Dadu R, Iyer P, et al.: Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid. 2020; 30(9): 1288–1296. PubMed Abstract | Publisher Full Text | Free Full Text
• 2.  Zhang Q, Xu S, Song Q, et al.: Predicting central lymph node metastasis in papillary thyroid cancer: A nomogram based on clinical, ultrasound and contrast-enhanced computed tomography characteristics. Oncol. Lett. 2024; 28(4): 478.
• 3.  Hameed OF, Makt oof ZA, Al-Deewan MA: Clinicopathological study of thyroid gland cancer among selected sample Basrah province between 2019–2022. Ro. J. Med. Pract. 2024; 19(2): 169–172. Publisher Full Text
• 4.  Mobini G-R, Yousefi H, Shojaeian A, et al.: Association of serum miR-375, miR-155 and miR-146b levels with distinguish of papillary thyroid cancer from benign thyroid masses among Iranian patients. Egyptian Journal of Medical Human Genetics. 2023; 24(1): 48. Publisher Full Text
• 5.  Moghoofei M, Mostafaei S, Nesaei A, et al.: Epstein–Barr virus and thyroid cancer: The role of viral expressed proteins. J. Cell. Physiol. 2019; 234(4): 3790–3799.
• 6.  Yu S-T, Ge J-N, Li R-C, et al.: Is Epstein-Barr Virus Infection Associated With Thyroid Tumorigenesis?—A Southern China Cohort Study. Front. Oncol. 2019; 9: 312. PubMed Abstract | Publisher Full Text | Free Full Text
• 7.  Ghafouri-Fard S, Shirvani-Farsani Z, Taheri M: The role of microRNAs in the pathogenesis of thyroid cancer. Non-coding RNA research. 2020; 5(3): 88–98.
• 8.  Qian H, Maghsoudloo M, Kaboli PJ, et al.: Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155. Int. J. Med. Sci. 2024; 21(14): 2781–2798. PubMed Abstract | Publisher Full Text | Free Full Text
• 9.  Lao TD, Nguyen MT, Nguyen DH, et al.: Upregulation of miRNA-155 in nasopharyngeal carcinoma patients. Iran. J. Public Health. 2021; 50(8): 1642–1647. PubMed Abstract | Publisher Full Text | Free Full Text
• 10.  Zhao C-X, Zhu W, Ba Z-Q, et al.: The regulatory network of nasopharyngeal carcinoma metastasis with a focus on EBV, lncRNAs and miRNAs. Am. J. Cancer Res. 2018; 8(11): 2185.
• 11.  Shechter O, Sausen DG, Gallo ES, et al.: Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments. Int. J. Mol. Sci. 2022; 23(22): 14389. PubMed Abstract | Publisher Full Text | Free Full Text
• 12.  Zhang Y, Li J, Wang X, et al.: Single-cell and multi-omics analysis identifies TRIM9 as a key ubiquitination regulator in pancreatic cancer. Front. Oncol. 2024; 14: 1387932. Publisher Full Text
• 13.  Moutabian H, Radi UK, Saleman AY, et al.: MicroRNA-155 and cancer metastasis: Regulation of invasion, migration, and epithelial-to-mesenchymal transition. Pathology-Research and Practice. 2023; 250: 154789. PubMed Abstract | Publisher Full Text
• 14.  Zhang W, Ji W, Zhao X: MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1. BMC Cancer. 2019; 19: 1011–1093. PubMed Abstract | Publisher Full Text | Free Full Text
• 15.  Liu C-G, Chen J, Goh RMW-J, et al.: The role of tumor-derived extracellular vesicles containing noncoding RNAs in mediating immune cell function and its implications from bench to bedside. Pharmacol. Res. 2023; 191: 106756. PubMed Abstract | Publisher Full Text
• 16.  Li H, Chen Y, Zhao L, et al.: Plasma EBV DNA, IL-6, and VEGF levels as predictive and prognostic biomarkers in nasopharyngeal carcinoma. Virol. J. 2024; 21(1): 182.
• 17.  Al-Ghamdi AS, Hakemi M, Rahmani F, et al.: Association of serum miR-375, miR-155 and miR-146b levels with distinguish of papillary thyroid cancer from benign thyroid masses among Iranian patients. Egypt. J. Med. Hum. Genet. 2023; 24(1): 23.
• 18.  Liu Y, Geng H, Liu X, et al.: A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma. PLoS One. 2021; 16(5): e0251676. PubMed Abstract | Publisher Full Text | Free Full Text
• 19.  Liu X, Li K, Liu Y, et al.: MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer. Biomark. Res. 2022; 10: 10. Publisher Full Text
• 20.  Wu Y, Nasifu L, He B, et al.: The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis. Mol. Diagn. Ther. 2023; 28(4): 507.
• 21.  Wood CD, Halder S, Palmer S, et al.: Enhancer control of microRNA miR-155 expression in Epstein-Barr virus-infected B cells. J. Virol. 2016; 90(1): 290–301.
• 22.  Tang Q, et al.: EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells. BMJ Open Cancer Res. 2020; 10.
• 23.  Castro-Muñoz JL, Maestri D, Yoon L, et al.: Histone variant H2A.Z cooperates with EBNA1 to maintain Epstein-Barr virus latent epigenome. MBio. 2025; 16(8): e0030225–e0030225. PubMed Abstract | Publisher Full Text | Free Full Text
• 24.  Xu S, et al.: miR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1. BMC Cancer. 2019; 19: 1093.
• 25.  Maiocchi S, Collins EN, Akerman AW, et al.: Plasma microRNA quantification protocol. Vessel Plus. 2023; 7: 27. Publisher Full Text
• 26.  Zhang X, et al.: Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Mol. Cancer. 2024; 23: 156.
• 27.  Salman AE, Khalil MA, Al-Esawi AOJ: EBNA-1 Regulation of miRNA-155 in Papillary Thyroid Carcinoma: A Case-Control Study in Iraqi Patients. [Dataset]. Figshare. 2025. Publisher Full Text

Current Reviewer Status: ?

VERSION 1

PUBLISHED 23 Dec 2025

Reviewer Report 10 Aug 2026

Basim Mohammed Khashman, University of Baghdad, Baghdad, Iraq 

Approved with Reservations

VIEWS 0

Reviewer Report 24 Jan 2026

Arwa Mujahid Al-Shuwaikh, Microbiology, College of Medicine, Al-Nahrain University, Kadhimiya, Baghdad, Iraq 

Approved

VIEWS 0